FindTrial
Sign In

A systematic review of the efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease

A systematic review of the efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease - Mucolytics in patients with stable chronic obstructive pulmonary disease

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000053404
Enrollment
Unknown
Registered
2024-01-21
Start date
2023-04-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease(COPD)

Interventions

None listed

Sponsors

Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: chronic obstructive pulmonary disease (COPD)

Exclusion criteria

Exclusion criteria: Subjects with chronic bronchitis without evidence of fixed airflow limitation (FEV1%<70) Subjects started on mucolytics as a treatment for COPD exacerbations Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO)

Design outcomes

Primary

MeasureTime frame
COPD exacerbations hospitalization—

Secondary

MeasureTime frame
duration of antimicrobial therapy duration of exacerbation duration of disability time to first exacerbation St. George's Respiratory Questionnaire score forced expiratory volume in one second forced vital capacity adverse events serious adverse events mortality cost-effectiveness—

Countries

Japan

Contacts

Public ContactHIROSHI OHNISHI

Kochi Medical School, Kochi University Department of Respiratory Medicine and Allergology

honi@kochi-u.ac.jp088-880-2345

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026